Dr. Zarrabi's research interests are centered on advancing treatment strategies for GU cancers. He has contributed to studies evaluating the efficacy of triplet therapy—combining androgen deprivation therapy (ADT), androgen receptor (AR)-targeted therapy, and chemotherapy—in metastatic castration-sensitive prostate cancer (mCSPC). Findings from pivotal trials such as PEACE1 and ARASENS have demonstrated improved overall survival in patients with high-volume disease, leading to triplet therapy becoming a new standard of care for select patients.
In addition to his work on triplet therapy, Dr. Zarrabi has explored the use of metronomic cyclophosphamide in metastatic castrate-resistant prostate cancer (mCRPC), investigating its potential benefits and genomic correlates . He has also co-authored research on bispecific PSMA antibodies and CAR-T cell therapies, highlighting their promise in treating mCRPC and the challenges associated with their development.
His clinical practice encompasses the management of prostate, bladder, and kidney cancers, with a particular focus on integrating innovative therapies into patient care.